AS Rheumatologic Causes A combined mix of genetic and environmental factors is believed to trigger ankylosing spondylitis, but the exact cause is unknown. Studies have shown that most people with ankylosing spondylitis possess the gene for HLA-B27. A person with the gene for HLA-B27 is not guaranteed to build up ankylosing spondylitis; however, having the gene increases the probability of developing ankylosing spondylitis. It is felt that in a few social people, illness of the intestines with particular bacteria may trigger an reaction to trigger the joint swelling in people with the gene for HLA-B27, eventually resulting in the advancement of ankylosing spondylitis.The trial shall be conducted at up to 175 investigational sites in THE UNITED STATES, Europe and Asia-Pacific. Sufferers in the trial must be at least 18 years of age and diagnosed with CML within half a year to enrollment prior. Approximately 500 sufferers will be randomized 1:1 to standard dosages of ponatinib or imatinib . Escalation of the imatinib dose to 600 mg or 800 mg each day is permitted. Related StoriesDr. Paul Liu called 2015 Distinguished Alumnus for contributions to leukemia researchResearchers determine new way to help AML individuals avoid a relapsePotential fresh drug target for severe myeloid leukemia The MMR rate at 12 a few months of treatment may be the primary endpoint of the trial.